Online Program Home
  My Program

Abstract Details

Activity Number:
Register
533 - Biopharmaceutical Section P.M. Roundtable Discussion (Added Fee)
Type: Roundtables
Date/Time: Wednesday, August 2, 2017 : 12:30 PM to 1:50 PM
Sponsor: Biopharmaceutical Section
Abstract #323621
Title: Unblinded Sample Size Re-Estimation for Complex Trials
Author(s): Chris Holland*
Companies: Amgen
Keywords: unblinded ; sample size re-estimation
Abstract:

Methods that allow for unblinded sample size re-estimation while protecting the overall type I error in a clinical trial have been around for close to 20 years, yet use of these methods are not very widespread. Potential reasons may include regulatory challenges, operational concerns, software limitations, or uncertainty over how to implement such methods for more complex situations such as those involving time-to-event endpoints and testing of secondary endpoints. In this roundtable, we will discuss obstacles to implementing unblinded sample size re-estimation and ideas for navigating around such obstacles with a particular focus on issues relating to more complex trials.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2017 program

 
 
Copyright © American Statistical Association